Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNF114 | Q9Y508 | 1/20 | 0.78 |
| ▸ | YAP1 | P46937 | 2/20 | 0.70 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122626 | 0.89 | RNF114 (0.83) | RNF114YAP1TEAD4L3MBTL1CACNA1H | |
| SCHEMBL27465865 | 0.85 | RNF114 (0.88) | RNF114YAP1TEAD4L3MBTL1ACHE | |
| SCHEMBL23518678 | 0.84 | RNF114 (0.91) | RNF114YAP1TEAD4L3MBTL1CACNA1H | |
| SCHEMBL30688878 | 0.82 | RNF114 (0.88) | RNF114YAP1TEAD4CACNA1HCACNA1C | |
| SCHEMBL28969681 | 0.80 | RNF114 (0.70) | RNF114YAP1TEAD4L3MBTL1CACNA1H | |
| SCHEMBL29129845 | 0.79 | RNF114 (0.69) | RNF114YAP1TEAD4L3MBTL1CACNA1H | |
| SCHEMBL28969657 | 0.78 | RNF114 (0.64) | RNF114YAP1TEAD4L3MBTL1CACNA1H | |
| SCHEMBL21393070 | 0.76 | YAP1 (0.69) | RNF114YAP1TEAD4L3MBTL1KDM4E | |
| SCHEMBL25546052 | 0.74 | RNF114 (0.59) | RNF114YAP1TEAD4L3MBTL1CACNA1H | |
| SCHEMBL21392773 | 0.74 | YAP1 (1.00) | RNF114YAP1TEAD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064080-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2021119159-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | RNF114 663/4885YAP1 1544/4885TEAD4 825/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | RNF114 169/4885YAP1 2264/4885TEAD4 2885/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | RNF114 663/4885YAP1 1544/4885TEAD4 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.